New drug cocktail aims to fight Hard-to-Treat cancers
NCT ID NCT06320405
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests whether combining three drugs—axatilimab, retifanlimab, and paclitaxel—is safe and effective for people with advanced or metastatic solid tumors. The study will enroll 38 adults whose cancer has spread or not responded to prior treatment. Researchers will monitor side effects and check if tumors shrink or stabilize.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axatilimab, retifanlimab, and paclitaxel
What this could lead to
If it works, this could point toward a new treatment option for people with advanced or metastatic solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial with only 38 participants, so results may not apply to everyone. The combination may cause serious side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact